Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Novavax, Inc. Jumped 22.8% in August

By Brian Orelli, PhD – Sep 10, 2018 at 4:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Clinical trial progress has investors excited about the vaccine company's future.

What happened

Shares of Novavax (NVAX 8.12%) jumped 22.8% in August, according to data provided by S&P Global Market Intelligence. This came after Novavax reported clinical trial progress for its vaccine ResVax during the company's second-quarter earnings report.

So what

Novavax reached an agreement with the Food and Drug Administration: The readout of a clinical trial testing ResVax, the company's vaccine against respiratory syncytial virus (RSV) in pregnant women, could be used to get the vaccine approved. The trial is designed to show that the vaccine can immunize infants to RSV while still in utero.

The company was previously guiding that the analysis, scheduled for the first quarter of 2019, would be an interim look at the data -- so the agency signing off on it being a final analysis will accelerate a potential approval. If the data are positive, Novavax plans to submit to the FDA and to European regulators in the first quarter of 2020.

An August 2018 calendar

Image source: Getty Images.

Novavax is also making progress on its influenza vaccine, NanoFlu. The FDA agreed that the company can take an accelerated approval route by comparing the immunogenicity -- the ability to create antibodies -- of its vaccine to already-approved vaccines. The strategy would allow Novavax to run a trial in the second half of 2019, potentially submitting the data around the same time as ResVax is submitted.

Now what

The regulatory updates last month are certainly good news for Novavax. But they don't really reduce the risk of investing in the biotech, since Novavax still needs to produce positive clinical trial data in order to take advantage of the new rules. Fortunately investors won't have to wait too much longer, with clinical trial data for both products expected in four to seven months.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.